Navigation Links
Kendle Announces First Quarter 2009 Results
Date:5/6/2009

CINCINNATI, May 6 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today reported net income of $886,000 or $0.06 per share for the first quarter 2009 compared with net income of $4.1 million or $0.27 per diluted share for the first quarter 2008. On a pro forma basis, net income for the first quarter of 2009 was $0.47 per diluted share compared with $0.38 per diluted share in the first quarter of 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO)

First Quarter 2009 Results

Net service revenues for the quarter ended March 31, 2009, totaled $108.1 million, a decrease of 5 percent compared with the same period in 2008. Excluding the impact of foreign exchange rates, revenues for the quarter increased 8 percent compared with the same period in 2008.

Income from operations for the three months ended March 31, 2009, was $8.1 million or 7.5 percent of net service revenues versus $14.0 million or 12.2 percent of net service revenues for first quarter 2008. The reduction in operating income is largely attributable to the decline of net service revenues for the quarter. Excluding the impact of foreign exchange rates, income from operations for the period ended March 31, 2009 would have been $11.4 million or 9.3 percent of net service revenues on a constant currency basis.

Effective Jan. 1, 2009, Kendle adopted APB 14-1 which increased interest expense for additional non-cash interest amounting to $1.7 million and $1.5 million for the periods ended March 31, 2009 and 2008 respectively.

The effective tax rate for
'/>"/>

SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... (PDL) (Nasdaq: PDLI ) today announced that it ... $0.50 per share to all stockholders owning shares of PDL ... As previously announced, the conversion rate for the Company,s ... to 140.571 shares of common stock per $1,000 principal amount ...
... 1 Maven Biotechnologies today announced that the company ... for Allergy and Infectious Disease (NIAID), part of the ... imaging technology for label-free protein microarrays and cell-based ... through the federal stimulus package initiative for Biomedical Research, ...
... The Culex quinquefasciatus mosquito poses a significant ... elephantiasis-causing worms and encephalitis-inducing viruses. An international team of ... the SIB Swiss Institute of Bioinformatics sequenced its genome ... published in today,s issue of Science, describe results from ...
Cached Biology Technology:Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics 2Major disease-vector mosquito reveals the secrets of its immune system 2
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2
... When we absorb new information, the human brain reshapes itself ... new knowledge kept, and how does that capacity to adapt ... senile dementia later in our lives? Dr. Yaniv Assaf ... new way to track the effect of memory on brain ...
... Arizona researchers have added another piece to the ... to treat patients in cardiac arrest, "passive ventilation" significantly ... ventilation." The study, published in an online edition ... patients who had suffered a cardiac arrest outside a ...
... Jerusalem have succeeded for the first time in devising ... mechanism that enables networks of neurons to efficiently decode ... lead to the upgrading of computer algorithms for faster ... the development of innovative treatments for auditory problems among ...
Cached Biology News:A window into the brain 2Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Hebrew U. researchers shed light on the brain mechanism responsible for processing of speech 2
... ovens are designed to create the ideal environment ... (ambient to 99.9C) , Variable speed control ... samples, whether it be for washing or hybridizing ... current temperature inside the chamber, ,is situated above ...
... magnetic particle based purification systems provide high ... any sample. They offer increased throughput and ... systems- KingFisher, KingFisher mL and KingFisher 96, ... l. Each system consists of an instrument, ...
... is the latest edition to the famous ... an extra large diameter exhaust port for ... panel allows precise setting and control of ... handling large quantities and samples , ...
... Thermo Savant SpeedVac Concentrators set the standard ... SC110A SpeedVac uses a combination of centrifugal force, ... a single run., SC110A comes equipped with:, , ... chemical compatibility , ...
Biology Products: